menu
    • menu
    [{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Cipla"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PUR1800","moa":"Proto-oncogene c-Src (SRC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Pulmatrix","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Pulmatrix"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cullgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmatrix \/ Cullgen","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Cullgen"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PUR1800","moa":"Proto-oncogene c-Src (SRC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR1800","moa":"Proto-oncogene c-Src (SRC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Medicines Evaluation Unit","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PUR1800","moa":"Proto-oncogene c-Src (SRC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Medicines Evaluation Unit","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Medicines Evaluation Unit"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"PUR1800","moa":"Proto-oncogene c-Src (SRC)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Nocion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Nocion Therapeutics"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix \/ Sensory Cloud"}]

    Find Clinical Drug Pipeline Developments & Deals by Pulmatrix

    Menu

    Pulmatrix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG001419

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cullgen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Pulmatrix and Cullgen Announce Proposed Merger

                            Details : The combined company will focus on targeted protein degradation technology with three programs, including CG001419, a potential first-in-class, highly active small molecule.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : CG001419

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cullgen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Pulmatrix Stops PUR1900 Phase 2B Enrollment To Preserve Cash

                            Details : Under the amendment, Cipla and Pulmatrix agreed to halt patient enrollment in the Ph2b study of PUR1900 (itraconazole) at 8 subjects, with Cipla assuming sole responsibility for its development.

                            Product Name : Pulmazole

                            Product Type : Other Small Molecule

                            Upfront Cash : $22.0 million

                            August 01, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Mannkind

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind

                            Details : MannKind will grant Pulmatrix a royalty free, exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of PUR3100, a proprietary formulation of dihydroergotamine.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Mannkind

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug P...

                            Details : PUR3100 dry powder inhaler is under development as an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the acute treatment of migraine.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 07, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

                            Details : PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ technology, which is investigated for the treatment of acute migraine.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 19, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydr...

                            Details : PUR3100 (Dihydroergotamine) is under development as an orally inhaled DHE engineered with iSPERSE™ for the acute treatment of migraine. The PUR3100 formulation is designed to disperse to the deep lung and rapidly enter the systemic circulation.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Poten...

                            Details : PUR3100 (dihydroergotamine) is under development as an orally inhaled DHE engineered with iSPERSE™ for the acute treatment of migraine. The PUR3100 formulation is designed to disperse to the deep lung and rapidly enter the systemic circulation.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 25, 2023

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PUR1800

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immu...

                            Details : PUR1800 is a narrow spectrum Kinase Inhibitor, engineered with our iSPERSE™ technology, being developed for the treatment of acute exacerbations in chronic obstructive pulmonary disease (AECOPD). PUR1800 targets p38 MAP kinases (p38MAPK), Src kinases, ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 23, 2023

                            Lead Product(s) : PUR1800

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 28, 2022

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

                            Details : PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 07, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth